GILD: Strong HIV growth, new launches, and oncology advances drive portfolio momentum
The event highlighted a robust, diversified portfolio with major advances in HIV prevention and treatment, including strong Yeztugo uptake and new long-acting options. Oncology and immunology pipelines are advancing, with anito-cel poised for launch and new I&I data expected soon.Based on Gilead Sc…